JP2016523907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523907A5 JP2016523907A5 JP2016523869A JP2016523869A JP2016523907A5 JP 2016523907 A5 JP2016523907 A5 JP 2016523907A5 JP 2016523869 A JP2016523869 A JP 2016523869A JP 2016523869 A JP2016523869 A JP 2016523869A JP 2016523907 A5 JP2016523907 A5 JP 2016523907A5
- Authority
- JP
- Japan
- Prior art keywords
- dioxo
- carbazole
- carboxamide
- fluoro
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- -1 2-hydroxypropan-2-yl Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- ZRYMMWAJAFUANM-INIZCTEOSA-N (7s)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5h-carbazole-1-carboxamide Chemical compound C1[C@@H](C(C)(C)O)CCC2=C1NC1=C2C(C2=C(C(=CC=C2)N2C(C3=CC=CC(F)=C3N(C)C2=O)=O)C)=C(F)C=C1C(N)=O ZRYMMWAJAFUANM-INIZCTEOSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- WQLRVJLVBJTPDC-INIZCTEOSA-N CC(C)([C@@H](CC1)Cc2c1c1c(-c3cccc(N(C(C=C4N5C=CC=C4Cl)=O)C5=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O Chemical compound CC(C)([C@@H](CC1)Cc2c1c1c(-c3cccc(N(C(C=C4N5C=CC=C4Cl)=O)C5=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O WQLRVJLVBJTPDC-INIZCTEOSA-N 0.000 description 2
- UGOUGTGKDWPLNV-UCFFOFKASA-N CC(C)([C@@H](CC1)Cc2c1c(C(c1cccc(N(C(C=C3N4C=CC=C3F)=O)C4=O)c1C)=C(CC1C(N)=O)F)c1[nH]2)O Chemical compound CC(C)([C@@H](CC1)Cc2c1c(C(c1cccc(N(C(C=C3N4C=CC=C3F)=O)C4=O)c1C)=C(CC1C(N)=O)F)c1[nH]2)O UGOUGTGKDWPLNV-UCFFOFKASA-N 0.000 description 1
- OILCFDXBRQHLMC-INIZCTEOSA-N CC(C)([C@@H](CC1)Cc2c1c1c(-c3cccc(N(C(C=C4N5C=CC=C4F)=O)C5=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O Chemical compound CC(C)([C@@H](CC1)Cc2c1c1c(-c3cccc(N(C(C=C4N5C=CC=C4F)=O)C5=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O OILCFDXBRQHLMC-INIZCTEOSA-N 0.000 description 1
- FPEKPVWYNZREQW-OAHLLOKOSA-N CC(C)([C@H](CC1)Cc2c1c1c(-c3cccc(N(C(c4cccc(F)c4N4)=O)C4=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O Chemical compound CC(C)([C@H](CC1)Cc2c1c1c(-c3cccc(N(C(c4cccc(F)c4N4)=O)C4=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O FPEKPVWYNZREQW-OAHLLOKOSA-N 0.000 description 1
- CJKYBOFIPNUNMH-NRFANRHFSA-N CC(C)(c(cc1)cc2c1c(C(c1cccc(N(C(C=C3N4C=CC=C3Cl)=O)C4=O)c1C)=C(C)C[C@@H]1C(N)=O)c1[nH]2)O Chemical compound CC(C)(c(cc1)cc2c1c(C(c1cccc(N(C(C=C3N4C=CC=C3Cl)=O)C4=O)c1C)=C(C)C[C@@H]1C(N)=O)c1[nH]2)O CJKYBOFIPNUNMH-NRFANRHFSA-N 0.000 description 1
- RPQWRQVJFPCCAW-NRFANRHFSA-N CC(C)(c1ccc2c(C(c3cccc(N(C(c4cccc(F)c4N4)=O)C4=O)c3C)=C(C)C[C@@H]3C(N)=O)c3[nH]c2c1)O Chemical compound CC(C)(c1ccc2c(C(c3cccc(N(C(c4cccc(F)c4N4)=O)C4=O)c3C)=C(C)C[C@@H]3C(N)=O)c3[nH]c2c1)O RPQWRQVJFPCCAW-NRFANRHFSA-N 0.000 description 1
- CJSGAKAHWDXMND-IBGZPJMESA-N Cc(c(C(c1c([C@H](C2)C(N)=O)[nH]c3cc(CCO)ccc13)=C2F)ccc1)c1N(C(C=C1N2C=CC=C1F)=O)C2=O Chemical compound Cc(c(C(c1c([C@H](C2)C(N)=O)[nH]c3cc(CCO)ccc13)=C2F)ccc1)c1N(C(C=C1N2C=CC=C1F)=O)C2=O CJSGAKAHWDXMND-IBGZPJMESA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839141P | 2013-06-25 | 2013-06-25 | |
| US61/839,141 | 2013-06-25 | ||
| PCT/US2014/043978 WO2014210085A1 (en) | 2013-06-25 | 2014-06-25 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523907A JP2016523907A (ja) | 2016-08-12 |
| JP2016523907A5 true JP2016523907A5 (index.php) | 2017-07-06 |
| JP6353529B2 JP6353529B2 (ja) | 2018-07-04 |
Family
ID=51210830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523869A Expired - Fee Related JP6353529B2 (ja) | 2013-06-25 | 2014-06-25 | 置換されたテトラヒドロカルバゾールおよびカルバゾールカルボキサミド化合物 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9334290B2 (index.php) |
| EP (1) | EP3013814B1 (index.php) |
| JP (1) | JP6353529B2 (index.php) |
| KR (1) | KR102346508B1 (index.php) |
| CN (1) | CN105358546B (index.php) |
| AR (1) | AR096721A1 (index.php) |
| AU (1) | AU2014302548B2 (index.php) |
| BR (1) | BR112015030723A8 (index.php) |
| CA (1) | CA2916500A1 (index.php) |
| CL (1) | CL2015003635A1 (index.php) |
| CY (1) | CY1119371T1 (index.php) |
| DK (1) | DK3013814T3 (index.php) |
| EA (1) | EA026729B1 (index.php) |
| ES (1) | ES2636652T3 (index.php) |
| HR (1) | HRP20171031T1 (index.php) |
| HU (1) | HUE034460T2 (index.php) |
| IL (1) | IL243296B (index.php) |
| LT (1) | LT3013814T (index.php) |
| MA (1) | MA38648B1 (index.php) |
| MY (1) | MY176631A (index.php) |
| PE (1) | PE20160519A1 (index.php) |
| PH (1) | PH12015502630A1 (index.php) |
| PL (1) | PL3013814T3 (index.php) |
| PT (1) | PT3013814T (index.php) |
| RS (1) | RS56371B1 (index.php) |
| SI (1) | SI3013814T1 (index.php) |
| SM (1) | SMT201700422T1 (index.php) |
| TN (1) | TN2015000529A1 (index.php) |
| TW (1) | TWI648272B (index.php) |
| UY (1) | UY35625A (index.php) |
| WO (1) | WO2014210085A1 (index.php) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2916504A1 (en) | 2013-06-25 | 2014-12-31 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| PT3461821T (pt) | 2014-10-24 | 2020-08-05 | Bristol Myers Squibb Co | Compostos de indol carboxamida úteis como inibidores de quinase |
| AU2015335783B2 (en) | 2014-10-24 | 2019-10-03 | Bristol-Myers Squibb Company | Tricyclic atropisomer compounds |
| TWI676618B (zh) * | 2014-10-24 | 2019-11-11 | 美商必治妥美雅史谷比公司 | 三環化合物 |
| EP3478148B1 (en) | 2016-07-01 | 2021-08-04 | Brio Device LLC | Intubation stylet with video feed |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| WO2018102785A2 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| KR102462896B1 (ko) * | 2016-12-20 | 2022-11-02 | 브리스톨-마이어스 스큅 컴퍼니 | 테트라히드로카르바졸 카르복스아미드 화합물의 제조 방법 |
| WO2019208805A1 (ja) | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| EP4313023A1 (en) | 2021-04-02 | 2024-02-07 | Biogen MA Inc. | Combination treatment methods of multiple sclerosis |
| MX2024009770A (es) * | 2022-02-15 | 2024-08-19 | Hoffmann La Roche | Procesos para la preparacion de derivados de 1,2,3,5,6,7-hexahidro -s-indaceno. |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| AU2005304473A1 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| EP1831227B1 (en) | 2004-12-17 | 2013-06-19 | Glenmark Pharmaceuticals S.A. | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
| BRPI0608252A2 (pt) | 2005-03-10 | 2010-04-06 | Cgi Pharmaceuticals Inc | entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas |
| CN101268048A (zh) * | 2005-09-16 | 2008-09-17 | 瑟瑞耐克斯有限公司 | 咔唑衍生物 |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| ES2390135T3 (es) | 2005-11-22 | 2012-11-06 | Merck Sharp & Dohme Corp. | Compuestos tricíclicos útiles como inhibidores de quinasas |
| JP2010502751A (ja) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ，インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
| CA2663178C (en) | 2006-09-11 | 2016-01-12 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
| US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
| US8431569B2 (en) | 2007-12-13 | 2013-04-30 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| US8318132B2 (en) | 2008-02-14 | 2012-11-27 | Siemens Medical Solutions Usa, Inc. | Imaging agents for detecting neurological dysfunction |
| GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
| EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
| EA019041B1 (ru) * | 2008-12-19 | 2013-12-30 | Бристол-Маерс Сквибб Компани | Карбазолкарбоксамидные соединения, применимые в качестве ингибиторов киназы |
| CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| CN102822171B (zh) | 2010-03-26 | 2015-09-02 | 默克专利有限公司 | 作为自分泌运动因子抑制剂的苯并萘啶胺类 |
| WO2011159857A1 (en) * | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| CN103429595B (zh) | 2010-11-15 | 2015-10-21 | Viiv保健英国有限公司 | Hiv复制的抑制剂 |
| BR112013029620A2 (pt) | 2011-05-17 | 2016-09-06 | Hoffmann La Roche | inibidores de tirosina quinase de bruton |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
-
2014
- 2014-06-24 TW TW103121681A patent/TWI648272B/zh not_active IP Right Cessation
- 2014-06-24 UY UY0001035625A patent/UY35625A/es unknown
- 2014-06-24 AR ARP140102388A patent/AR096721A1/es unknown
- 2014-06-25 CN CN201480035611.8A patent/CN105358546B/zh not_active Expired - Fee Related
- 2014-06-25 JP JP2016523869A patent/JP6353529B2/ja not_active Expired - Fee Related
- 2014-06-25 US US14/314,602 patent/US9334290B2/en active Active
- 2014-06-25 TN TN2015000529A patent/TN2015000529A1/en unknown
- 2014-06-25 DK DK14740094.9T patent/DK3013814T3/en active
- 2014-06-25 SI SI201430268T patent/SI3013814T1/sl unknown
- 2014-06-25 MA MA38648A patent/MA38648B1/fr unknown
- 2014-06-25 BR BR112015030723A patent/BR112015030723A8/pt not_active Application Discontinuation
- 2014-06-25 WO PCT/US2014/043978 patent/WO2014210085A1/en not_active Ceased
- 2014-06-25 HR HRP20171031TT patent/HRP20171031T1/hr unknown
- 2014-06-25 LT LTEP14740094.9T patent/LT3013814T/lt unknown
- 2014-06-25 EA EA201592287A patent/EA026729B1/ru not_active IP Right Cessation
- 2014-06-25 RS RS20170904A patent/RS56371B1/sr unknown
- 2014-06-25 EP EP14740094.9A patent/EP3013814B1/en active Active
- 2014-06-25 PE PE2015002665A patent/PE20160519A1/es active IP Right Grant
- 2014-06-25 PL PL14740094T patent/PL3013814T3/pl unknown
- 2014-06-25 ES ES14740094.9T patent/ES2636652T3/es active Active
- 2014-06-25 MY MYPI2015704738A patent/MY176631A/en unknown
- 2014-06-25 HU HUE14740094A patent/HUE034460T2/en unknown
- 2014-06-25 KR KR1020167001632A patent/KR102346508B1/ko not_active Expired - Fee Related
- 2014-06-25 CA CA2916500A patent/CA2916500A1/en not_active Abandoned
- 2014-06-25 SM SM20170422T patent/SMT201700422T1/it unknown
- 2014-06-25 AU AU2014302548A patent/AU2014302548B2/en not_active Ceased
- 2014-06-25 PT PT147400949T patent/PT3013814T/pt unknown
-
2015
- 2015-11-26 PH PH12015502630A patent/PH12015502630A1/en unknown
- 2015-12-15 CL CL2015003635A patent/CL2015003635A1/es unknown
- 2015-12-22 IL IL243296A patent/IL243296B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/067,915 patent/US20160194338A1/en not_active Abandoned
-
2017
- 2017-06-16 US US15/625,417 patent/US9850258B2/en active Active
- 2017-09-06 CY CY20171100943T patent/CY1119371T1/el unknown
- 2017-11-10 US US15/809,437 patent/US10106559B2/en active Active
-
2018
- 2018-09-25 US US16/140,750 patent/US10435415B2/en active Active
-
2019
- 2019-08-22 US US16/547,675 patent/US20190382416A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523907A5 (index.php) | ||
| JP2016523908A5 (index.php) | ||
| JP2014521735A5 (index.php) | ||
| JP2014508752A5 (index.php) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2016508134A5 (index.php) | ||
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| JP2017504611A5 (index.php) | ||
| JP2015501783A5 (index.php) | ||
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2015523397A5 (index.php) | ||
| JP2016522835A5 (index.php) | ||
| JP2018109022A5 (index.php) | ||
| CY1123837T1 (el) | Ενωσεις για την χρηση στη θεραπεια μεταστασεων στον εγκεφαλο σε ασθενη με καρκινο του μαστου erbb2+ | |
| HRP20160135T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka | |
| EA201890852A1 (ru) | Соли валбеназина и их полиморфы | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| RU2015104537A (ru) | Способы лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2016528301A5 (index.php) | ||
| JP2015508103A5 (index.php) | ||
| JP2016530283A5 (index.php) | ||
| WO2015042078A8 (en) | Substituted aminopyrimidine compounds and methods of use | |
| JP2014513110A5 (index.php) | ||
| JP2015536964A5 (index.php) |